Robert Bayless
Family · Spokane, WANPI 1306555826
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$981
- AstraZeneca$730
- Teva Pharmaceuticals USA, Inc.$572
- Exact Sciences$412
- Amgen$283
- GSK$278
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $981 |
| AstraZeneca | 32 | $730 |
| Teva Pharmaceuticals USA, Inc. | 29 | $572 |
| Exact Sciences | 20 | $412 |
| Amgen | 14 | $283 |
| GSK | 24 | $278 |
| Otsuka America Pharmaceutical, Inc. | 15 | $277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $276 |
| Novo Nordisk | 15 | $273 |
| Boehringer Ingelheim | 12 | $251 |
| Pfizer | 13 | $220 |
| Lilly USA, LLC | 15 | $215 |
| Johnson & Johnson | 7 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $143 |
| Corcept Therapeutics | 6 | $107 |
| Dexcom, Inc. | 5 | $99 |
| Lundbeck LLC | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Astellas Pharma US Inc | 5 | $79 |
| Bayer | 5 | $79 |
| Medtronic | 3 | $77 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| Neurocrine Biosciences, Inc. | 4 | $71 |
| Merck | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Nevro Corp. | 1 | $34 |
| Viiv Healthcare Company | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Edwards Lifesciences | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
| Sanofi | 1 | $13 |
How this compares
$6,171 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $55,135 |
| FarxigaDapagliflozin Propanediol | 60 | $52,719 |
| OzempicSemaglutide | 38 | $46,114 |
| JardianceEmpagliflozin | 36 | $39,478 |
| TrulicityDulaglutide | 18 | $17,490 |
| JanuviaSitagliptin Phosphate | 18 | $15,196 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,517 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,971 |
| Serevent DiskusSalmeterol Xinafoate | 13 | $5,542 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 126 | $3,253 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,034 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $2,975 |
| Gabapentin | 96 | $1,610 |
| Omeprazole | 65 | $1,303 |
| Rosuvastatin Calcium | 46 | $1,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $730 | $63,23677 claims |
| PfizerEliquis | $220 | $55,13557 claims |
| Novo NordiskOzempic | $273 | $46,11438 claims |
| Boehringer IngelheimJardiance | $251 | $39,47836 claims |
| Lilly USA, LLCTrulicity | $215 | $17,49018 claims |
| MerckJanuvia | $45 | $15,19618 claims |
| GSKBreo Ellipta | $278 | $8,97117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Spokane
- Zelda SwainSpokane$83K
- Cheryl SomersSpokane$31K
- Lance VarnsSpokane$11K
- Jennifer BanksSpokane$9K
- Ruth MolletSpokane$6K
- Jennifer NiemiSpokane$5K
- Melissa TuftsSpokane$5K
- Rachel GalazkaSpokane$5K
- Sharla PetersonKenmore$192K
- Savannah MorganRenton$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.